CLOV vs ALHC

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 22, 2026

CLOV

44.5
AI Score
VS
ALHC Wins

ALHC

51.6
AI Score

Investment Advisor Scores

CLOV

45score
Recommendation
HOLD

ALHC

52score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric CLOV ALHC Winner
Revenue 1.49B 1.36B CLOV
Net Income 55.34M -100.81M CLOV
Net Margin 3.7% -7.4% CLOV
Operating Income 55.34M -85.90M CLOV
ROE 14.7% -53.5% CLOV
ROA 7.7% -13.1% CLOV
Total Assets 720.33M 770.79M ALHC
Current Ratio 1.50 1.63 ALHC
Free Cash Flow 131.55M 102.88M CLOV

Relative Price Performance (Last 90 Days)

CLOV 1M: +3.2% · 3M: +9.1% ALHC 1M: +7.1% · 3M: -56.7%

Current Technical Phase

CLOV

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (1.2% over 20 days), RSI 54

RSI (14): 54.3 · Price: $4.72

ALHC

Markdown
Sell / avoid

Price below a falling SMA50 (slope -25.3%), weak momentum, RSI 41

RSI (14): 41.2 · Price: $8.42

Fundamentals Snapshot

Metric CLOV ALHC
Market Cap — —
Forward P/E 31.5 13.0
Trailing P/E — 44.4
Revenue (TTM) — —
Revenue Growth 0.6% 0.3%
Gross Margin 0.2% 0.1%
Operating Margin 0.0% 0.0%
EPS -0.05 0.19
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, ALHC is currently the stronger investment candidate, winning 2 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.